Clinical trialNCT04840199TerminatedPhase 2Interventional

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment44CMVCytomegalovirusHIV Infections

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This was an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who were on antiretroviral therapy (ART)-mediated suppression. Participants were randomly assigned to receive either letermovir once daily or no anti-CMV treatment, for 48 weeks. The primary hypothesis of this study was that letermovir would cause a greater reduction in plasma soluble receptor for tumor necrosis factor type II (sTNFRII) levels than no anti-CMV treatment at weeks 46/48.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Peter Hunt, MD
University of California, San Francisco, HIV/AIDS CRS
Study ChairKOL profile →
clinicaltrials.gov ↗
Sara Gianella, MD
University of California, San Diego, AntiViral Research Center CRS
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucsd Antiviral Research Center Crs (site 701)
San Diego, California, United States
Ucsf Hiv/aids Crs (site 801)
San Francisco, California, United States
University of Colorado Hospital Crs
Aurora, Colorado, United States
Northwestern University Crs
Chicago, Illinois, United States
Massachusetts General Hospital Crs (mgh Crs)
Boston, Massachusetts, United States
Washington University Therapeutics (wt) Crs
St Louis, Missouri, United States
Weill Cornell Chelsea Crs (7804)
New York, New York, United States
Weill Cornell Uptown Crs (7803)
New York, New York, United States
University of Rochester Adult Hiv Therapeutic Strategies Network Crs
Rochester, New York, United States
Cincinnati Clinical Research Site
Cincinnati, Ohio, United States
Case Clinical Research Site
Cleveland, Ohio, United States
Penn Therapeutics, Crs
Philadelphia, Pennsylvania, United States
University of Pittsburgh Crs
Pittsburgh, Pennsylvania, United States
Vanderbilt Therapeutics (vt) Crs
Nashville, Tennessee, United States
University of Washington Positive Research Crs
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Letermovir →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Apr 2022
Primary completion: 30 Nov 2023
Completion: 30 Nov 2023
Last update posted: 4 Mar 2025
Registered enrollment: 44
Registry id: NCT04840199

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.